Get the Stockscreener App
5.35
1.83%
-0.10
After Hours:
5.12
-0.23
-4.30%
Bioage Labs Inc stock is traded at $5.35, with a volume of 505.31K.
It is down -1.83% in the last 24 hours and up +11.00% over the past month.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
See More
Previous Close:
$5.45
Open:
$5.46
24h Volume:
505.31K
Relative Volume:
3.65
Market Cap:
$191.80M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.63%
1M Performance:
+11.00%
6M Performance:
+55.98%
1Y Performance:
-73.95%
1-Day Range:
$5.245
$5.46
1-Week Range:
$5.245
$5.80
52-Week Range:
$2.88
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
Name
Bioage Labs Inc
Sector
Phone
510-806-1445
Address
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
5.35 | 195.38M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
141.11 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.71 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
440.00 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Dec-10-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-09-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-21-24 | Initiated | Citigroup | Buy |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-21-24 | Initiated | Morgan Stanley | Overweight |
View All
Bioage Labs Inc Stock (BIOA) Latest News
Short interest data insights for BioAge Labs Inc.2025 Volume Leaders & Accurate Technical Buy Alerts - newser.com
BioAge Labs (NASDAQ:BIOA) Given Sell (E+) Rating at Weiss Ratings - MarketBeat
Can BioAge Labs Inc. stock sustain revenue growthPortfolio Return Summary & Real-Time Volume Analysis Alerts - newser.com
Can trapped investors hope for a rebound in BioAge Labs Inc.2025 Analyst Calls & Growth Focused Entry Reports - newser.com
What drives BioAge Labs Inc stock priceEarnings Surprise Analysis & Minimal Investment Trading - earlytimes.in
Developing predictive dashboards with BioAge Labs Inc. data2025 Key Lessons & Weekly Top Gainers Trade List - newser.com
Can momentum traders help lift BioAge Labs Inc.M&A Rumor & Weekly High Conviction Ideas - newser.com
Using Ichimoku Cloud for BioAge Labs Inc. technicals2025 Top Gainers & Low Risk Entry Point Guides - newser.com
Will BioAge Labs Inc. stock outperform tech sector in 20252025 Geopolitical Influence & Capital Protection Trading Alerts - newser.com
How strong is BioAge Labs Inc. (Y7G) stock earnings growth2025 Trading Volume Trends & High Accuracy Swing Entry Alerts - newser.com
Analyzing net buyer seller activity in BioAge Labs Inc.Market Rally & Low Drawdown Investment Ideas - newser.com
BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
How high can BioAge Labs Inc. stock go2025 Buyback Activity & Precise Buy Zone Tips - newser.com
BioAge Labs files for mixed shelf offering of up to $250 millionSEC filing - MarketScreener
BioAge Labs Files $250 Million Mixed Shelf - MarketScreener
Is BioAge Labs Inc a good long term investmentStock Valuation Metrics & Your Free Entry to Smart Investing Starts Here - earlytimes.in
What analysts say about BioAge Labs Inc Y7G stockMarket Capitalization Trends & Reap the Rewards of Patience + Planning - earlytimes.in
BioAge Labs Inc Y7G Stock Analysis and ForecastFibonacci Extensions & Build Winning Portfolio - earlytimes.in
BioAge Labs, Inc. (NASDAQ:BIOA) institutional owners may be pleased with recent gains after 74% loss over the past year - simplywall.st
Bioage Labs Inc Stock (BIOA) Financials Data
There is no financial data for Bioage Labs Inc (BIOA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.54%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):